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Abstract
Background: Pakistan is endemic to hepatitis B and C infections. Alarming rise in hepatitis C virus (HCV) infection has been 
noticed in some areas of  Sindh with an increasing risk for co-infection frequency in this region.
Objective: To estimate the burden of  HBV/HCV infection in Hyderabad Pakistan. 
Methods: ELISA and Nucleic acid Amplification test were performed to detect viruses. SPSS and online calculator were used 
for statistical analysis.
Results: From a total of  108 seropositive hepatitis patients, 36.1% (n=39) were found HCV RNA-positive. Non-significant dif-
ferences were observed in the frequencies of  HCV infection for both genders [OR=0.735, CI (95%) 0.307-1.761, p<0.05]. The 
percentage of  HBV DNA detection among 108 HCV-seropositive cases was 17.9% (n=19). However, HCV-HBV co-infection 
in HCV-RNA positive cases was determined in 48.7% (n=19) cases with non-significant difference in both genders [OR=1.51, 
CI (95%) = 0.38 - 5.96, p< 0.05]. Analysis suggested weakly positive correlation between HCV mono-infection and HCV-HBV 
co-infection and age (r =0.184, and r =0.1231), respectively.
Conclusion: The study demonstrates a high prevalence of  HBV co-infection among active hepatitis C patients of  Hyderabad.
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atitis C, Hyderabad, Sindh.
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Introduction
Hepatitis B and Hepatitis C identified as the most prev-
alent causes of  hepatitis in diverse groups of  population 
including general population, health care workers, chil-
dren and patients with short-term hepatitis and chronic 
liver diseases. Nearly 2 billion people are infected with 
Hepatitis  B  Virus  (HBV) and the annual mortality rate 
approaches about 0.9 million around the world in people 
suffering from Hepatitis B associated complications1,2. 
Hepatitis C virus (HCV) is also one of  the major sources 
of  chronic hepatitis and affects about 71 million people 
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with the magnitude of  about 0.4 million deaths annually 
around the world3,4.
Hepatitis B virus belong to Hepadnavirus family having a 
circular dsDNA genome with one nick, but, complete -ve 
DNA strand (~3.2 kb in length). The other complemen-
tary strand is of  +ve polarity and incomplete with a large 
gap, approximately 1.7 kb in length5. Although HBV vac-
cine was introduced more than three decades ago6, the in-
fectivity ratio of  hepatitis B is still exceedingly distressing, 
affecting around 350-400 million individuals with chron-
ic infection worldwide, of  whom 75% belong to Asia7-9. 
HBV infection is endemic to Pakistan with a seroprev-
alence of  2.4% (range 1.4–11.0%) in healthy adults10,11 
and 32.6% in patients with liver disease12.  HBV infection 
approximately affects 9 million people in Pakistan13. HBV 
transmission mostly occurs through parenteral route, that 
is, unsafe blood transfusions and use of  unsterilized or 
re-used syringes and needles10,11,13.
Hepatitis C Virus (HCV) is an enveloped, blood-borne 
infectious agent belongs to Flaviviridae family with ssRNA 
genome of  positive polarity14. Hepatitis C is estimated to 
affect 171 million people worldwide with the global in-
fectivity ratio of  ~3%15-17. HCV is widely spread amongst 
the population of  Pakistan with the mean sero-preva-
lence rate of  6.8% among healthy adults and infectivity 
ratio of  more than 5% in the general population across 
the country17. 
Nearly 10 million people in Pakistan are affected with 
Hepatitis C infection18 and most of  them belong to ru-
ral and periurban areas of  Pakistan where the sources of  
HCV spread are relatively many, such as, routine practice 
of  multiple injections, re-use of  syringes, unsterilized use 
of  needles in ear and nose piercing and lack of  proper 
blood screening and transfusion procedures, etc. A high 
sero-prevalence of  HCV up to 28.6% is described in as-
ymptomatic individuals in Nausheroferoz district, Sindh, 
suggesting HCV is widely present in certain rural areas19. 
Because HCV and HBV share the same route of  trans-
mission and the chances of  co-infection are likely more 
particularly in areas with high burden of  infection by 
these viruses. Limited research reports are available to de-
scribe the co-infection frequency in different geographi-
cal regions of  Pakistan and the data from Hyderabad and 
other areas of  Sindh is actually scarce. HBV-HCV co-in-
fection frequency is reported as 9% in hepatitis patients 
of  Peshawar and Abbottabad cities of  Pakistan20. In few 
other studies conducted in some rural areas of  Punjab 
province, HBsAg and anti-HCV antibody was found in 
0.19% in healthy blood donors21 and 3.2% in health care 
workers22.  The rural and urban areas in Sindh province, 
except the mega city Karachi, are largely investigated for 
the prevalence of  mono-infection by HBV and HCV and 
lack a co-infection parameter19,23-25. A few studies con-
ducted in Karachi show dual HBV-HCV prevalence as 
0.11% in household children26, 1.3% in viral hepatitis pa-
tients27 and 3.1% in patients of  hepatitis B28. In one com-
munity based study Bhatti and Manzoor described 2.5% 
dual HBV-HCV prevalence in rural areas of  Sindh29. A 
previous study by Junejo et al. presented 3.9% co-preva-
lence of  HBsAg and anti-HCV infection in the ocular pa-
tients of  Hyderabad30. In the present study, we investigat-
ed more than hundred hepatitis C seropositive samples 
from HCV patients of  Hyderabad. All anti-HCV positive 
samples were processed for NAT to find out active HCV 
cases.  HBV co-infection was tracked in both anti-HCV 
and HCV-RNA positive samples and the data obtained 
was correlated with age and gender for the statistical anal-
ysis. The data presented here describes the prevalence of  
HBV co-infection in the active HCV patients of  Hyder-
abad city of  Pakistan.
 
Methods
The study was approved by the Institutional Review 
Board [R.No.5 (60)] of  University of  Sindh, Jamshoro. 
In the present study, blood samples from hepatitis pa-
tients were collected and processed from Asian Institute 
of  Medical Sciences (AIMS), one of  the main diagnos-
tic centers of  Hyderabad. The minimum sample size for 
both mono and co-infections were determined to be 87 
and 90 using the following parameters; the Z value of  
standard normal distribution was calculated from 95% 
(CI) with a margin of  error of  5%, and about 6% of  
HCV active infection17 and 6.2% of  HCV-HBV co-infec-
tion respectively10. A total of  108 non-duplicate samples 
from different age groups found positive for anti HCV 
antibodies on the basis of  the Electro-Chemi-Lumines-
cence Immunoassay (ECLIA) using Elecsys and Cobas 
e Immunoassay Analyzer were included in the current 
study. The samples were processed for Nucleic acid Am-
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plification Test to detect the HCV RNA and HBV DNA. 
The detection was performed on Cobas® 480 System 
USA Hemilton (involving separate extraction and detec-
tion) using Cobas® HCV and HBV test kit (Roche) as 
per manufacturer’s instructions. The statistical analysis of  
data was either performed using SPSS IBM version 20 or 
using online statistics calculator [Select Statistical Services 
UK (www.select-statistics.co.uk) and Graph-pad prism 
(www.graphpad.com)].The variables categorized were 
further scrutinized using Fisher’s exact test and bivariate 
correlation analysis. 
Results
HCV RNA positive cases are independent of  gender
For the estimation of  active HCV infection, an overall of  
108 non-duplicate anti-HCV antibodies positive samples 
from hepatitis patients of  different age groups were pro-
cessed to detect HCV RNA using quantitative RT-PCR. 
A total of  79 samples (74.5%) from male and 29 samples 
(27.3%) from female patients were processed. The overall 
percentage of  HCV RNA-positive and negative samples 
was found to be 36.1% (n=39) and 63.9% (n=67) respec-
tively (Figure 1). Categorically, a total of  12 (34.1%) cases 
among females and 27 (41.3%) among males were found 
to be positive (Table 1, Figure 2). The OR with CI (95%) 
for gender was calculated to be 0.735 (CI 95% = 0.307-
1.761), while the p-values using a Fisher’s exact test was 
determined to be 0.490 at α=0.05, suggesting statistically 
non-significant differences in the frequencies of  HCV in-
fection among both genders.
 
 
Figure 1. Bar diagram displaying the percentages of HCV mono-infection 
and HCV-HBV co-infection. 
Age and HCV RNA positive cases have a weak pos-
itive correlation.
To explore if  age has any correlation with HCV-RNA 
positive cases, a Pearson’s correlation co-efficient be-
tween age and HCV RNA positive cases was calculated 
to be r = 0.184, suggesting a weakly positive correlation 
between age and HCV RNA positive cases. We also cate-
gorized the data into various age groups. The magnitude 
of  the age group was randomly chosen to be 10.  Table 1 
displays the number of  HCV-RNA positive and negative 
cases for different age groups in each category and is ex-
pressed both in absolute and relative values (percentages). 
The OR, CI (95%), and p-values calculated for various 
age groups gender-wise are also shown in Table 1.
The maximum active HCV percentage in male category 
was found in the age group of  61-70 years (60%) while in 
case of  female category the maximum active HCV per-
centage was seen in the age group of  11-20 years (100%). 
However due to very small number of  samples the com-
parative analysis could not be performed for these age 
groups. In order to avoid bias, the age groups having 
mathematically substantial sample size (i.e. age groups 
ranging from 21 to 60) were then compared for both 
genders.  The highest positive cases (66.6%) were seen 
for female category in the age group of  41-50, howev-
er, statistically non-significant differences for HCV-RNA 
positive cases between male and female were found in 
various age groups.
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HCV-HBV co-infection is independent of  gender
To determine the co-infection frequency, HCV sero-pos-
itive samples (n=106) were further processed in combi-
nation with Hepatitis B virus detection. Out of  39 HCV 
RNA positive samples, 19 (48.7%) were found to be pos-
itive for HCV-HBV co-infection, while 20 (51.3%) were 
negative for co-infection. (Figure 1).  Categorically, a total 
of  14/27 (51.8%) cases among male and 05/12 (41.6%) 
among female were calculated to be positive for HCV-
HBV co-infection (Table 2, Figure 2). The OR with CI 
(95%) for gender was calculated to be 1.51 CI (95%) = 
(0.38 - 5.96), while the p-values using a Fisher’s exact test 
was determined to be 0.731 at α=0.05, suggesting an im-
partial effect of  gender on the HCV-HBV co-infection.
Table 1. Percentages of HCV-RNA positive and negative cases among male and female 
gender and age groups. The Odds ratio (OR), CI (95%) and p-values are mentioned for 




RNA 1 - 10 11 - 20 21 - 30 31 - 40 41 - 50 51 - 60 61 - 70 71 - 80 
  
 
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
Male Positive 0 (NA) 0 (NA) 2 (13.3%) 
11 
(37.9%) 7 (33.3%) 4 (50%) 3 (60%) 0 (NA) 




(62.1%) 14 (66.7%) 4 (50%) 2 (40%) 1 (NA) 
  Total 0 0 15 29 21 8 5 1 
Female Positive 0 (NA) 2 (100%) 5 (45.4%) 1 (12.5%) 2 (66.6%) 2 (40%) 0 (NA) 0 (NA) 
  Negative 0 (NA) 0 (00%) 6 (54.6%) 7 (87.5%) 1 (33.4%) 3 (60%) 0 (NA) 0 (NA) 












[0.1 – 5.58] 
1.5 




0.05) [NA] [NA] 0.09 0.23 1 1 [NA] [NA] 
                                      
  
Table 2. Percentages of HCV-HBV-RNA positive and negative cases among male and female 
gender and age groups. The odds ratio (OR), CI (95%) and p-values are mentioned for various 
age groups, gender-wise.  n = number, NA = Not Applicable, Co-CB = HCV-HBV Co-infection. 
                                      
   
Gender 
HCV-HBV 
Co-infection 1 - 10 11 - 20 21 - 30 31 - 40 41 - 50 51 - 60 61 - 70 71- 80 
    n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
Male Co-CB 0 (NA) 0 (NA) 2 (13.3%) 5 (17.2%) 2 (10%) 3 (37.5%) 2 (40%) 0 (00%) 
  Non-Co-CB 0 (NA) 0 (NA) 13 (86.7%) 
24 
(82.8%) 18 (90%) 5 (62.5%) 3 (60%) 
1 
(100%) 
  Total 0 0 15 29 20 8 5 1 
Female Co-CB 0 (NA) 1 (50%) 2 (18.8%) 0 (0%) 1 (33.3%) 1 (20%) 0 (NA) 0 (NA) 
  Non-Co-CB 0 (NA) 1 (50%) 9 (81.8%) 7 (100%) 2 (66.7%) 4 (80%) 0 (NA) 0 (NA) 
  Total 0 2 11 7 3 5 0 0 
  
OR 






[0.18-32.88] [NA] [NA] 
  
p-value 
(α = 0.05) [NA] [NA] 1 [NA] 0.356 1 [NA] [NA] 
 








Figure 2. Bar diagram displaying the percentages of HCV mono-infection and 








Figure 2. Bar diagram displaying the percentages of HCV mono-infection and 
HCV-HBV co-infection in both genders. 
Age and HCV-HBV co-infection cases have a weak 
positive correlation.
To explore if  age has any correlation with HCV-HBV 
co-infection, a Pearson’s correlation co-efficient between 
age and HCV-HBV co-infection cases was calculated to 
be r = 0.1231, suggesting a weakly positive correlation 
between age and HCV-HBV co-infection cases. We also 
categorized the data into various age groups. Once again 
the magnitude of  the age group was randomly chosen to 
be 10. The Table 2 displays the numbers of  HCV-HBV 
co-infection cases for different age groups in each cate-
gory and is expressed both in absolute and relative values 
(percentages). Table 2 also shows the OR, CI (95%), and 
p-values calculated for various age groups gender-wise. 
The maximum percentage HCV-HBV co-infection fre-
quency in male category was found in the age group of  
61-70 years (40%) while in case of  female category the 
maximum HCV-HBV coinfection frequency was seen 
in the age group of  11-20 years (50%). However due to 
very small numbers of  samples the comparative analysis 
could not be performed for these age groups. In order 
to avoid bias, the age groups having mathematically sub-
stantial sample size (i.e. age groups ranging from 21 to 
60) were then compared for both genders.  The highest 
positive cases (37.5%) for HCV-HBV co-infection were 
seen for male category in the age group of  51-60, howev-
er, statistically non-significant differences for HCV-HBV 
co-infection cases between male and female were found 
in various age groups.
Discussion
Pakistan is one of  the worst affected countries with the 
highest burden of  hepatitis B and hepatitis C viral infec-
tion. According to World Health Organization (WHO) 
report, nearly 12 million people in Pakistan are suffering 
from hepatitis B or C infections and the number is on 
continuous rise each year. In hepatitis B and C endem-
ic countries, dual HBV and HCV infection constitute a 
significant number of  patients. Infection with more than 
one hepatitis virus further aggravates the chronicity of  
disease in the population particularly with low socio-eco-
nomic status. Co-infection of  HBV and HCV has been 
reported from different countries of  world as these virus-
es share the same route of  transmission31-33. Patients with 
dual hepatitis are more susceptible and at greater risk of  
developing liver cirrhosis and hepatocellular carcinoma31. 
Anti-HCV prevalence is reported 5% and HBsAg as 2.4% 
in general population of  Pakistan26. However, prevalence 
of  hepatitis B and C varies in different geographical lo-
cations of  Pakistan, depending upon the extent of  expo-
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sure to the common risk factors, awareness and access of  
community to proper public health services. For example, 
in some rural areas of  Sindh,  HBV and HCV frequency 
was observed as 13% and 22% in pregnant woman and 
blood donors, respectively34. In few other studies expo-
sure of  HCV is observed even greater than 25% in the as-
ymptomatic people of  upper Sindh19,35  reflecting the fact 
that actual burden of  disease need to be measured and it 
varies with localities within the same province. It has been 
studied that among the patients of  chronic liver disease, 
HBV mono-infection prevalence is 10-46%, anti-HCV is 
40-60% 24 and co-infection frequency of  hepatitis B and 
C virus is 1-3%27,28.
In the current study, active HCV mono-infection was 
found in 36.1% cases and were simultaneously tracked 
for co-infection with HBV using NAT. Overall co-infec-
tion prevalence was observed as 17.9% in total anti-HCV 
positive samples (n=108) and 48% in HCV-RNA positive 
samples. This is a significantly higher frequency of  dual 
infection in comparison to previous studies in the same 
or different regions of  Pakistan. However, keeping in 
mind the higher frequency of  exposure (> 25%) to both 
hepatitis B and C in rural areas of  upper Sindh19,35, we 
presume that in hepatitis patients the chances for holding 
HBV and HCV dual infection are greater. In our study, 
we did not observe a significant statistical difference be-
tween single or dual infection of  HBV/HCV and gender. 
Some studies have shown that males have a high percent-
age of  infectivity as compared to the females but lack 
significant statistical values24,27. As has been described by 
others24,35-37, we also observed in our study that frequen-
cy of  mono or dual hepatitis increases with age and the 
maximum frequency (37.5%) is seen in age group of  51-
60. However the small sample size is a limitation of  the 
present study but it strongly upholds the view that there 
is an alarmingly high prevalence of  single or dual HBV/
HCV infection in the indigenous population of  Hyder-
abad. The study provides a future direction to explore the 
common associated risk factors and a molecular surveil-
lance with an increased sample size to estimate mono-in-
fection and co-infection frequency in this region.   
Conclusion
From the present study, we perceive that prevalence of  
HBV and HCV is widespread among the population but 
the actual burden of  disease is still not explored well in 
both symptomatic and asymptomatic individuals of  Hy-
derabad region. HCV is more widespread than HBV in-
fection perhaps due to the lack of  vaccine for HCV virus. 
Most of  the studies conducted in rural or urban areas of  
Sindh are based on serological methods rather than mo-
lecular detection of  viral nucleic acid to measure the ac-
tual prevalence of  disease. Therefore it is suggested that 
access to an accurate diagnosis should be provided to the 
poor population for the estimation of  true positive / ac-
tive HCV infection, proper management and prevention 
of  chronic illness.
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